Clinical Trial

Faecal Microbiota Transplantation for Liver Cirrhosis

Study acronym: CHiFT
Recruiting Phase 2/3
View on ClinicalTrials.gov →
Record status
This record was last updated January 24, 2025 (before its estimated May 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose is to investigate the effect of faecal microbiota transplantation (FMT) on complications, progression, and mortality of patients with liver cirrhosis. Further, the investigators want to examine the impact of FMT on the gut microbiota, gut barrier function, systemic inflammation, and immune function.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2021-06-18; most recent amendment 2025-01-21.
Status change: Not Yet Recruiting → Recruiting 2021-11-03
Trial Details
NCT Number NCT04932577
Lead Sponsor University of Aarhus
Collaborators: Aarhus University Hospital, Aalborg University Hospital, Odense University Hospital, Hvidovre University Hospital, Aalborg University, Esbjerg Hospital - University Hospital of Southern Denmark, Sjælland University Hospital
Conditions Liver Cirrhosis
Enrollment 220 participants
Start Date 2021-07-01
Primary Completion 2026-05-31 (estimated)
Study Completion 2027-05-31 (estimated)
Updated on ClinicalTrials.gov 2025-01-24